Securian Asset Management, Inc Ligand Pharmaceuticals Inc Transaction History

Securian Asset Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 08, 2021	SELL	$102.33 - $144.73 $153,801 - $217,529	-1,503 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$113.03 - $155.64 $11,303 - $15,563	-100 Reduced 6.24%	1,503 $197,000
Q1 2021 May 10, 2021	BUY	$99.52 - $215.83 $9,952 - $21,583	100 Added 6.65%	1,603 $244,000
Q3 2020 Nov 04, 2020	SELL	$89.56 - $126.72 $8,956 - $12,672	-100 Reduced 6.24%	1,503 $143,000
Q2 2020 Aug 06, 2020	SELL	$68.28 - $123.65 $6,828 - $12,365	-100 Reduced 5.87%	1,603 $179,000
Q1 2020 May 07, 2020	SELL	$63.37 - $107.88 $6,337 - $10,788	-100 Reduced 5.55%	1,703 $124,000
Q4 2019 Feb 04, 2020	SELL	$96.94 - $113.59 $31,990 - $37,484	-330 Reduced 15.47%	1,803 $188,000
Q3 2019 Nov 12, 2019	SELL	$86.25 - $120.16 $21,303 - $29,679	-247 Reduced 10.38%	2,133 $212,000
Q2 2019 Aug 05, 2019	SELL	$107.38 - $129.34 $10,738 - $12,934	-100 Reduced 4.03%	2,380 $272,000
Q1 2019 Apr 26, 2019	SELL	$105.93 - $142.47 $10,593 - $14,247	-100 Reduced 3.88%	2,480 $312,000
Q4 2018 Feb 04, 2019	BUY	$128.36 - $272.13 $331,168 - $702,095	2,580 New	2,580 $350,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.88B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Securian Asset Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Securian Asset Management, Inc with notifications on news.